The Lynx Group

SABCS 2017

CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer.
Read Article

Questions About Treating Patients Using a CDK4/6 Inhibitor
Dr Matthew Goetz addresses common questions that arise when patients with HER-positive metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor.
Read Article

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Read Article

The Use of Chemotherapy in the Metastatic Setting
Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy.
Read Article

The Mechanism of Action of CDK4/6 Inhibitors
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Read Article

HER2-Positive Breast Cancer and CDK4/6 Inhibitors
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.
Read Article

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.
Read Article

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Read Article

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
Read Article

Page 1 of 2

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: